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ABSTRACT:
CYP2C9 is an important drug-metabolizing enzyme that metabo-
lizes, e.g., warfarin, antidiabetics, and antiphlogistics. However,
the endogenous regulation of this enzyme is largely unknown. In
this study, we examined the role of GATA transcription factors in
the gene expression of CYP2C9. We investigated four putative
GATA binding sites within the first 200 base pairs of CYP2C9
promoter at the positions I: 173/170, II: 167/164, III: 118/
115, and IV: 106/103. Luciferase activity driven by a wild-
type CYP2C9 promoter construct was strongly up-regulated in
Huh-7 cells upon cotransfection with expression plasmids for
GATA-2 and GATA-4, whereas mutations introduced into GATA
binding site III or I and II reduced this induction to a significant
extent. Electrophoretic mobility shift assays revealed specific
binding of GATA-4 and GATA-6 to the oligonucleotides contain-
ing GATA binding sites I and II. Furthermore, the association of
GATA-4 with CYP2C9 promoter was confirmed by chromatin
immunoprecipitation assays in HepG2 cells. Taken together,
these data strongly suggest an involvement of liver-specific
transcription factor GATA-4 in the transcriptional regulation of
CYP2C9.
CYP2C9 is an important enzyme involved in the metabolism of a
large number of different drugs. It is the second most abundant
cytochrome P450 enzyme in human liver (Miners and Birkett, 1998),
and it is responsible for the transformation of approximately 16% of
all used therapeutics including drugs like warfarin, losartan, phenyt-
oin, tolbutamide, and different antiphlogistics (Urquhart et al., 2007).
CYP2C9 is polymorphically expressed. The most common allelic
variants in whites are CYP2C9*2 and CYP2C9*3, which occur at a
frequency of approximately 7 and 11%, respectively. Carriers of these
variants show a slower metabolism toward CYP2C9 substrates and a
considerably higher risk for adverse drug reactions (Kirchheiner and
Brockmoller, 2005). An important example is the occurrence of
bleeding complications upon treatment of CYP2C9 slow metabolizers
with warfarin (Flockhart et al., 2008).
The CYP2C9 activity varies significantly within wild-type carriers
(Yasar et al., 2001; Scordo et al., 2002; Sandberg et al., 2004). Possible
reasons for this phenomenon are the inducibility of CYP2C9 by different
substrates, interindividual differences in the constitutive CYP2C9 expres-
sion (Peyvandi et al., 2004; Kirchheiner and Brockmoller, 2005), as well
as polymorphic variations of the regulatory region (Kramer et al., 2008).
Thus, it was demonstrated that CYP2C9 expression can be regulated by
hepatocyte nuclear factor (HNF)4 and its coregulators peroxisome pro-
liferator-activated receptor- coactivator and steroid receptor coactiva-
tor 1 via direct repeat 1 promoter elements (Kawashima et al., 2006;
Martinez-Jimenez et al., 2006). CYP2C9 promoter activity is moreover
influenced by HNF3 (Bort et al., 2004) and by a cross-talk between
constitutive androstane receptor and pregnane X receptor with HNF4
upon induction by rifampicin (Chen et al., 2005).
In this study, we focus on the zinc finger transcription factor family
GATA, which is an important group of transcriptional regulators. The
GATA family comprises six different members, GATA-1 to GATA-6,
which recognize the consensus sequence (A/T)GATA(A/G).
GATA-1, -2, and -3 regulate the expression of genes involved in the
development of blood cells (Harigae, 2006; Wu et al., 2007).
GATA-4, -5, and -6 are specifically expressed in cardiac tissue
(Peterkin et al., 2005) and play a key role in the transcriptional regula-
tion of different genes involved in cardiac development and cardiomyo-
cyte differentiation (Reiter et al., 1999; Crispino et al., 2001). In addition,
GATA-4 is also expressed in liver and regulates here the expression of
different liver detoxifying enzymes and transporters (Zhu et al., 2004;
Kwintkiewicz et al., 2007; Sumi et al., 2007).
In silico analysis of the proximal CYP2C9 promoter indicates the
presence of multiple GATA binding motifs, which prompted us to
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study the possible involvement of these factors in the regulation of
CYP2C9 expression. In this study, we show by luciferase gene re-
porter assay, electrophoretic mobility shift assay (EMSA) and chro-
matin immunoprecipitation (ChIP) analysis that CYP2C9 can be reg-
ulated by the transcription factor GATA-4. Furthermore, GATA-4-
dependent activation of CYP2C9 is down-regulated by an important
coregulator of GATA-4, Friend of GATA-2 (FOG-2).
Materials and Methods
Plasmid Constructs. Fragments of different length of CYP2C9 promoter
were subcloned into the MluI/XhoI cloning sites of pGL3-Basic vector (Pro-
mega, Madison, WI) upstream of the luciferase gene (constructs 2C9_735,
2C9_421, and 2C9wt_331) (Table 1; Fig. 1B). Constructs with destructive
mutations at all detected hypothetical GATA binding sites [positions (173/
170, site I), (167/164, site II), (118/115, site III), and (106/103,
site IV)] alone (constructs 2C9_331_m1, 2C9_331_m2, 2C9_331_mut3,
and 2C9_331 _m4) or in combination (site I and site II, construct
2C19_331_mut1  2) were generated using GeneTailor kit (Invitrogen,
Carlsbad, CA) (Table 1; Fig. 1B).
The human pCMV-FLAG2-GATA2 and mouse pcDNA1.1-GATA4 ex-
pression plasmids were kind gifts from Prof. Gokhan Hotamisliglil (Harvard
University, Boston, MA) and Prof. Jeffery Molkentin (Children’s Hospital
Medical Center, Cincinnati, OH), respectively. The human pcDNA3-FOG-2
wild-type construct as well as human pcDNA3-FOG-2_1-247 (expresses trun-
cated protein missing the GATA-4 binding zinc finger domain) were kind gifts
from Prof. Erik Svensson (University of Chicago, Chicago, IL) (Svensson
et al., 2000).
Transient Transfections. Huh-7 human hepatoma cells were grown at
37°C in Dulbecco’s modified Eagle’s medium, supplemented with 10% fetal
bovine serum, and 1% penicillin/streptomycin (Invitrogen). One day before
transient transfection, 2  105 Huh-7 cells were plated into 12-well plates.
Two micrograms of the different pGL3-Basic expression vectors carrying
CYP2C9 promoter fragments of different lengths as well as the constructs
mutated at the different GATA sites were cotransfected with 0.5 g of mouse
pcDNA1.1-GATA4, human pCMV-FLAG2-GATA2, or 0.5 g of pcDNA3.1
empty vector (negative control). To investigate possible interactions between
GATA and FOG proteins, GATA-2 or GATA-4 constructs were cotransfected
with different amounts of a wild-type (pcDNA3-FOG2) or 1 g of a mutated
FOG construct (pcDNA3_FOG-2_1-247). Transient transfections were per-
formed by using Lipofectamine 2000 (Invitrogen) according to manufacturer’s
recommendations. Cells were harvested and analyzed for luciferase activity at
24 (GATA cotransfections; Fig. 2, A and B) or 48 h (cotransfections with
GATA and FOG; Fig. 5) after cotransfection. In each transfection mixture, 2
ng of the plasmid harboring Renilla luciferase gene (pRL SV40; Promega) was
included as an internal control for the transfection efficiency. Luciferase
activity is therefore expressed as a ratio of firefly luciferase activity (in
arbitrary units) to the corresponding activity of the Renilla luciferase. All
experiments were performed in triplicates and repeated three times.
Electrophoretic Mobility Shift Assay. Nuclear protein extracts from
Huh-7 cells were prepared according to the protocols of Dignam et al. (1983)
and Nakabayashi et al. (1991) with slight modifications. Eight different dou-
ble-stranded (ds) oligonucleotides comprising 50 base pairs (bp) of the
CYP2C9 promoter were generated by annealing sense and antisense oligonu-
cleotides (Table 1). The oligonucleotides were carrying the hypothetical
GATA binding sites in wild-type or in mutated form. Oligonucleotide labeling
was carried out using 32P (PerkinElmer Life and Analytical Sciences,
Waltham, MA) and T4 DNA polynucleotide kinase system (Invitrogen) in a
final reaction volume of 25 l. The mixes were incubated at 37°C for 15 min.
The reaction was stopped with 5 l of Na2EDTA (0.2 M). For binding
reactions, 4% glycerol, 8 mM HEPES (Sigma-Aldrich, St. Louis, MO) (pH-
7.9), 0.6 mM MgCl2, 50 mM NaCl, 1 g of poly(dI-dC), 12.8 fmol of
32P-labeled ds oligonucleotide probe (approximately 20,000 cpm), and 4 g of
nuclear protein were mixed together in a total end volume of 25 l. After 15
min of preincubation at 37°C, the different labeled ds oligonucleotides were
added to the mixes and the complete mixture was again incubated at 37°C for
TABLE 1
Oligonucleotides used for cloning, EMSA, and ChIP experiments
Primers for cloning were designed based on the CYP2C9 sequence (GenBank accession number NT_030059). Fragments for reporter constructs were PCR amplified from a
CYP2C9 construct encompassing the first 1.8 kb of CYP2C9 5-flanking region [a gift from Dr. Mia Sandberg Lundblad (Lundbeck Inc., Copenhagen, Denmark), construct slightly
modified]. Nonsense mutations in GATA sites I to IV were introduced into construct 2C9_331_wt, resulting in the plasmids 2C9_331_m1, 2C9_331_m2, 2C9_331_m3,
2C9_331_m4, and 2C9_331_m12, respectively. 2C9wt12 and 2C9wt34: EMSA oligonucleotides containing wild-type GATA binding site I and II or GATA binding site III
and IV. 2C9mut1, 2C9m2, 2C9m3, 2C9m4, 2C9m12: oligonucleotides with destructive mutations in GATA binding site I, II, III, IV or I and II together. GATA binding sites are
underlined. Mutations that destroy any GATA motifs are highlighted in bold. ChIP Primer set was used in ChIP analysis leading to a PCR product of 225 bp of length. The PCR
product includes all four possible GATA binding sites.
Primer Name Sequence
Cloning primers Wild type
CYP2C9_735 fw 5-CAGACGCGTGCTATGAGCTGTGTGGC ACC
CYP2C9_421 fw 5-CAGACGCGTAATATACAAGG CATAGAATAT GG
CYP2C9_331 fw 5-CAGACGCGTCA GATTATTTACTTCAGTGCT
CYP2C9 rev 5-CAGCTCGAGTGAAGCCTTCTCTTCTTGTTAA
Mutant
CYP2C9_mut1_fw 5-CAAAGGACATTTTATTTTTTTTTGTATCAGTG
CYP2C9_mut1_rev 5-AAA AATAAAATGTCCTTTGGTCTTGTTCT
CYP2C9_mut2_fw 5-GACATTTTATTTTTATCTGTTTTAGTGGGTCAA
CYP2C9_mut2_rev 5-ACAGATAAAAATAAAATGTCCTTTGGTCTT
CYP2C9_mut3_fw 5-ATATAGTGGACCTAGGTTTTTGGTCAATTT
CYP2C9_mut3_rev 5-ACCTAGGTCCACTATATGCTCCTTCTGAAA
CYP2C9_mut4_fw 5-GGTGATTGGTCAATTAAAACATCAAAGAGG
CYP2C9_mut4_rev 5-AATTGACCAATCACCTAGGTCCACTATATG
CYP2C9_mut12_fw 5-CAAAGGACATTTTATTTTTTTTGTTTTTAGTG
CYP2C9_mut12_rev 5-AAA AATAAAATGTCCTTTGGTCTTGTTCT
EMSA oligonucleotides (forward)
2C19wt12 5-ACCAAAGGACATTTTATTTTTATCTGTATCAGTGGGTCAAAGTCCTTTCA
2C9wt34 5-ATATAGTGGACCTAGGTGATTGGTCAATTTATCCATCAAAGAGGCACACA
2C9mut1 5-ACCAAAGGACATTTTATTTTTTTTTGTATCAGTGGGTCAAAGTCCTTTC
2C9mut2 5-ACCAAAGGACATTTTATTTTTATCTGTTTTAGTGGGTCAAAGTCCTTTCA
2C9mut3 5-ATATAGTGGACCTAGGTTTTGGTCAATTTATCCATCAAAGAGGCACACAC
2C9mut4 5-ATATAGTGGACCTAGGTGATTGGTCA ATTAAAACATCAAAGAGGCACACAC
2C9mut12 5-ACCA AAGGACATTT TATTTTTTTT TGTTTTAGTG GGTCAAAGTC CTTTCA
Oligonucleotides used for ChIP
Primer set 5-CCAA CCAAGTACAG TGAAACT
5-TTAAGACAACCATGAGCTTGCACT
fw, forward; rev, reverse primers.
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15 min. For competition experiments, 50- and 100-fold excess of the respective
unlabeled ds oligonucleotide was added to the probe before the addition of
32P-labeled ds oligonucleotides. Supershift experiments were carried out by
adding 6 g of GATA-2, -3, -4, or GATA-6 antibody (sc-1235X, sc-268X,
sc-1237X, and sc-9055X; Santa Cruz Biotechnology, Inc., Santa Cruz, CA) to
the respective binding reaction before the addition of labeled oligonucleotides,
and samples were incubated on ice for 45 min. Finally, 5 l of loading buffer
were added to each sample. Protein-bound and unbound DNA were resolved
on a 4% none denaturing polyacrylamide gel. Dried gels were subjected to
autoradiography by using phosphorimager (Fujifilm BAS-1800; Fujifilm, To-
kyo, Japan).
Chromatin Immunoprecipitation. ChIP assay kit (Millipore Corporation,
Billerica, MA) was used according to the manufacturer’s protocol. HepG2
cells were grown at 37°C in small dishes in minimal essential medium
supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin (In-
vitrogen), as well as 1% sodium pyruvate and 1% none essential amino acids.
DNA-bound proteins were cross-linked to chromatin by adding 1% formalde-
hyde and incubated at 37°C. Harvested and lysed cells were sonicated to shear
the DNA to fragments of approximately 500 bp. DNA was precleared with
salmon sperm DNA/protein A agarose slurry and afterward incubated over-
night with 2 g of GATA-4 antibody (sc-1237X; Santa Cruz Biotechnology,
Inc.) or control IgG (rabbit normal IgG, sc-2027; Santa Cruz Biotechnology,
Inc.) at 4°C. The antibody/histone complexes were collected with salmon
sperm DNA/protein A agarose slurry rotating the mixes for 2 h at 4°C. The
immunoprecipitate was pelleted and washed with low and high salt containing
buffers and with TE buffer (10 mM Tris-HCl and 1 mM EDTA). The histone
complex was eluted from the antibody, and histone-DNA cross-links were
reversed at 65°C overnight. After treatment with proteinase K (QIAGEN,
Valencia, CA) and purification using QIAamp DNA Mini Kit (QIAGEN),
samples, including the input/sonicated DNA sample (positive control), were
subjected to touch-down polymerase chain reaction (PCR) using a primer pair,
which generates a 225-bp fragment including all four GATA sites of interest.
Statistical Analysis. Statistical differences in reporter gene activity among
CYP2C9 promoter constructs were determined by one-way analysis of vari-
ance followed by a Turkey’s post hoc test using GraphPad Prism version 5.00
for Windows (GraphPad Software Inc., San Diego, CA). A p-value threshold
of 0.05 was considered as statistically significant in all analyses.
Results
GATA Factors Activate the CYP2C9 Promoter. Analysis of the
CYP2C9 promoter revealed four putative GATA binding sites at the
positions (173/170), (167/164), (118/115), and (106/
103) (Fig. 1A). To investigate the influence of GATA transcription
factors on CYP2C9 expression, 5-deletion fragments of CYP2C9
promoter were cloned upstream to firefly luciferase gene into the
pGL3-Basic vector (Fig. 1B) and transiently transfected into Huh-7
cells together with GATA-2, -4, and -6 expression vectors. The
strongest effect was observed for GATA-2 and -4 transcription factors
(GATA-6 results are not shown). As demonstrated in Fig. 2, A and B,
both factors strongly up-regulate 331-bp long 5-deletion construct of
the wild-type CYP2C9 promoter. Identical up-regulation was also
observed for two other 5-deletion constructs, 435- and 735-bp long
(results not shown), which would suggest localization of the potential
GATA-responsive site(s) in the proximal CYP2C9 promoter region.
GATA-Dependent Up-Regulation of CYP2C9 Promoter Is Driven
by GATA Binding Site III. To investigate to which extent the in
silico-detected putative GATA binding sites are important for
CYP2C9 regulation, the 331-bp-long promoter constructs containing
2C9_-735                       -735
2C9_-421                                                             -421
2C9_-331                                                             -331
2C9_-331_m1                                                          -331
2C9_-331_m2                                                          -331 
2C9_-331_m3                                                          -331
2C9_-331_m4                                                          -331
2C9_-331_m1+2                                                        -331
Luc
Luc
Luc
Luc
Luc
Luc
Luc
Luc
TATC TATC
nnnn
nnnn
nnnn
nnnn
TATC TATC
GATT
GATTTATC
TATC
TATC GATT
TATCTATC
TATC TATC
TATC
TATC
nnnn
TATC GATT
nnnn
TATC TATC GATT
GATT TATC
TATC
GATT TATC
site I site II            site III         site IV
FIG. 1. Detected GATA motifs in CYP2C9 promoter and design of luciferase reporter constructs encompassing four possible GATA binding sites. A, the DNA sequence
surrounding four possible GATA binding sites of CYP2C9 gene promoter. The A of the first codon ATG is numbered as 1. GATA motifs I to IV are shown in upper
case and highlighted in bold. B, schematic representation of 5-truncated CYP2C9 promoter fragments cloned upstream to luciferase reporter gene. Numbers refer to
fragment length. Mutated GATA binding sites are indicated in italic.
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wild-type or mutant GATA binding motifs (Fig. 1B) were cotrans-
fected with GATA-2 or GATA-4 expression vectors into Huh-7 cells.
Artificial disruption of GATA sites I or II did not affect GATA-2- and
GATA-4-dependent up-regulation of luciferase activity (Fig. 2, A and
B). By contrast, disruption of the putative GATA site III caused a
drastic drop of GATA-2 and GATA-4 effects down to pGL3-Basic
level. We were surprised to find that an equally strong loss in
luciferase activity was observed for the CYP2C9 promoter construct
carrying combined GATA III mutations (Fig. 2, A and B).
The luciferase activity pattern in mock-transfected cells always
mimicked (although at a significantly lower level) the activity pattern
observed with GATA-2 and GATA-4 overexpression. This phenom-
enon might be explained by the endogenous expression of GATA
factors in the Huh-7 cell line (data not shown).
GATA-4 Binds to Two Different GATA Binding Sites in Prox-
imal CYP2C9 Promoter. Next, we investigated whether the putative
GATA binding sites interact with GATA transcription factor(s) using
electrophoretic mobility shift assay. Different wild-type and mutant
32P-labeled oligonucleotides comprising different combinations of
wild-type or disrupted forms of GATA binding sites (Fig. 3, A and B)
were incubated with nuclear extracts from Huh-7 cells. Protein-DNA
complexes were formed with both 2C9wt12 (comprises GATA
binding sites I and II) and 2C9wt34 (comprises GATA binding sites
III and IV) oligonucleotides (Fig. 3, A and B, lane 1). Mutation of site
I and II (Fig. 3A, lanes 2 and 3) did not affect the binding, whereas the
oligonucleotide containing both mutations (mut12; Fig. 3A, lane 4)
is completely devoid of any binding activity. Likewise, disruption of
the GATA site III (but not site IV) led to a significant loss of protein
binding activity (Fig. 3B, lanes 2 and 3). Taken together, these results
suggest binding of the nuclear factor to GATA site III as well as to
the GATA site III, which is consistent with the gene reporter data.
Next, we attempted to identify the protein that binds to these sites
using antibodies against different members of the GATA family
(GATA-2, GATA-3, GATA-4, and GATA-6). Among all antibodies
used, anti-GATA-4 and anti-GATA-6 were able to successfully su-
pershift the formation of the protein/oligonucleotide complex ob-
served with oligonucleotides 2C9wt1 and 2C9wt12 (Fig. 3A, lanes
10 and 11). Neither of these antibodies was found to shift the 2C9wt3
complex (Fig. 3B). These findings suggest that GATA-4 and GATA-6
can interact with CYP2C9 promoter.
GATA-4 Is Associated with CYP2C9 Promoter. To investigate
whether GATA-4 is indeed endogenously associated with the hypo-
thetical GATA binding sites within CYP2C9 promoter, we performed
a chromatin immunoprecipitation assay by using genomic DNA from
HepG2 cells and antibodies against GATA-4. Promoter fragments
were amplified by PCR using a primer set encompassing the putative
GATA binding sites (Table 1). As shown on Fig. 4 (lane 1), the primer
set was able to generate a PCR product that matches exactly with the
predicted promoter fragment containing the GATA sites in question.
No PCR product was observed with immune complexes formed by
control IgGs, demonstrating the specificity of the assay (Fig. 4, lane
2). This finding confirms that GATA-4 is associated with CYP2C9
promoter even in intact cells.
FOG-2 Counters the GATA-4-Dependent CYP2C9 Promoter
Activation. GATA proteins are known to be often coregulated by the
transcription factor family FOG, including the members FOG-1 and
FOG-2. In particular, FOG-2 interacts with GATA-4 and influences a
GATA-4-dependent transcriptional regulation of different target
genes. Several studies showed that a disruption of FOG-2/GATA-4
interaction can lead to pathological forms of heart development during
organogenesis (Tevosian et al., 1999; Svensson et al., 2000; Crispino
et al., 2001). To investigate whether FOG-2 is also involved in
GATA-4-dependent CYP2C9 promoter regulation, we used the lucif-
erase gene reporter approach cotransfecting GATA-4 and FOG-2
expression plasmids with the CYP2C9 promoter constructs used in
previous experiments. Figure 5 shows the cotransfection results for
promoter construct 2C19_331_wt, GATA-4, and FOG-2. Whereas
FIG. 2. GATA-2 and GATA-4 up-regulate CYP2C9 promoter in gene reporter
assay. Relative luciferase activities of CYP2C9 promoter fragments subcloned into
pGL3-Basic vector (Fig. 1B) and of pGL3-Basic control vector (negative control)
after cotransfection with pGATA2-CMV-FLAG2 (GATA-2) or pcDNA3.1 empty
vector (mock) (A) and pGATA4-pcDNA1.1 (GATA-4) or pcDNA3.1 empty vector
(mock) (B) in Huh-7 cells. All deletion constructs were in general highly up-
regulated upon cotransfection with GATA-2 or GATA-4. , p  0.01 for
2C9wt_331, 2C9_mut1_331, 2C9_mut2_331 (A), and 2C9wt_331 (B) co-
transfected with pcDNA3.1 against cotransfection with GATA2 (A) or GATA-4
(B). , p  0.001 for 2C9_mut1_331, 2C9_mut2_331, and 2C9_mut4_331
(B) cotransfected with pcDNA3.1 against cotransfection with GATA-4 (B). ,
p  0.001 for 2C9_331_mut12 or 2C9_331_mut3 versus 2C9_331_wt (A),
and , p  0.001 for 2C9_331_mut12 or 2C9_331_mut3 (B) versus
2C9_331_wt. Data are presented as mean values  S.D. of three independent
experiments. Each experiment was performed in triplicate.
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the cotransfection with only GATA-4 led to an expected up-regulation
of CYP2C9 promoter (Fig. 5, bar 2), the addition of FOG-2 attenuated
this effect. The extent of inhibition correlated with the amount of
transfected FOG-2 plasmid (Fig. 5, bars 3–6). In line with this result,
the inhibitory effect was clearly reduced when cotransfecting the
mutant construct pcDNA3-FOG-2_1-247 that lacks the fragment cod-
ing for the GATA-binding zinc finger domain (Fig. 5, bar 7). These
data strengthen the hypothesis that CYP2C9 is regulated by the
GATA-4 transcription factor.
Discussion
For the first time, we provide experimental evidence that GATA
transcription factors are involved in the regulation of CYP2C9 ex-
pression. This assumption is supported by the following facts: 1)
GATA-2 and -4 significantly increase the activity of CYP2C9 pro-
moter fragments containing potential GATA binding sites; 2) FOG-2,
a known regulator of GATA proteins, was found to modulate these
effects; and 3) physical interaction of GATA factors (GATA-4 in
particular) with the promoter was shown by ChIP and EMSA exper-
iments, indicating that such binding may occur both in vivo and in
vitro.
Which of the GATA family transcription factors are actually im-
portant for CYP2C9 regulation, and which of the four potential GATA
cis-elements in the promoter are their immediate targets? Whereas the
comprehensive answers to these questions are still not available, our
data would support the following hypotheses:
1. GATA-2, -4, and -6 displayed CYP2C9 promoter-regulating activ-
ity in various experimental approaches shown in this study. This
result is not surprising provided the high degree of conservation
between the DNA binding domains of different family members and
FIG. 3. GATA-4 binds to the oligonucleotides containing GATA binding motif I and II in EMSA analysis using nuclear extracts from Huh-7 cells. EMSA was performed
using double-stranded oligonucleotides (Table 1) comprising GATA binding site I and II (A) or GATA binding site III and IV (B), respectively, in wild-type (2C9 wt 12
or 2C9 wt 34) or mutated (2C9 mut 1, 2C9 mut 2, 2C9 mut 12, 2C9 mut3, 2C9 mut 4) forms. Nuclear extracts were prepared from Huh-7 cells. The binding complexes
are indicated by white arrows. Supershift experiments were performed by using antibodies against GATA-2, -3, -4, and -6. A successful competition was observed with
antibodies against GATA-4 and GATA-6 using oligonucleotide 2C19 wt 12 (Fig. 3A, lanes 10 and 11, indicated by black arrows). comp, competition reactions with cold
2C9 wt 12 (A) and 2C9 wt 34 (B). Additional competition controls were performed by using cold mutant oligonucleotides in combination with labeled wild-types
oligonucleotides (results not shown).
FIG. 4. GATA-4 associates with CYP2C9 promoter in HepG2 cells. GATA-4
binding to CYP2C9 promoter was analyzed by using ChIP assay. Immune com-
plexes precipitated with GATA-4 antibody and control IgG antibody were PCR
amplified using a primer set encompassing a fragment around all four putative
GATA binding sites. Successful amplification was seen in the agarose gel electro-
phoresis after immunoprecipitation with GATA-4 antibody. Additional negative
control was performed with a primer set generating an amplicon not containing any
GATA site (results not shown). Input is a positive PCR control, i.e., sonicated DNA
(starting material before immunoprecipitation).
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their ability to bind to the conserved GATA response element.
Therefore, it can be speculated that the selection of CYP2C9-
specific GATA factor should be resolved by the tissue-specific
expression of the particular GATA factor. It has previously been
shown that some liver-expressed cytochromes P450 and drug trans-
porters are regulated by GATA-4. These include CYP19 (Cai et al.,
2007), epoxide hydroxylase (Zhu et al., 2004), and the ATP-binding
cassette transporters ABCG5 and ABCG8 (Sumi et al., 2007). These
data suggest that GATA-4, which has previously been associated
mainly with the regulation of genes involved in heart development,
also seems to be important for the expression of genes implicated in
the drug metabolism or drug transport in the liver. Our findings are
further supported by the fact that liver cells predominantly express
only two members of GATA family, GATA-4 and to a much lesser
extent GATA-6, two important regulatory factors of liver-specific
gene expression (Molkentin, 2000).
2. To answer the question of which of the potential GATA binding
sites is actually more involved in the interaction with GATA factors,
a comparison of all results obtained for both putative double binding
sites is necessary. The ChIP assay gives ambiguous information
because the minimal length of the GATA site carrying promoter
fragment, which is a target of PCR amplification, is approximately
200 bp and it comprises all four predicted GATA binding elements.
The gene reporter assay indicates site III and III as binding
candidates. Both sites form specific complexes in EMSA; however,
only the site III complex was supershifted by GATA-4 and -6. In
addition, this sequence is strongly conserved in the proximal promoter
of the closely related CYP2C19. Therefore, this site can be suggested
as a most likely candidate for the interaction with GATA factor(s).
CYP2C9 has also been shown to be regulated by other transcription
factors including, e.g., HNF4 and HNF3 (Bort et al., 2004; Ka-
washima et al., 2006). Binding sites for these transcription factors are
located in direct neighborhood of the newly detected GATA sites
within the CYP2C9 promoter. It remains to be investigated to which
extent GATA factors are able to interact with these regulatory
proteins.
Transcriptional regulation of CYP2C9 by the GATA transcription
factor family might be partly responsible for interindividual differ-
ences in CYP2C9 activity seen in wild-type carriers of CYP2C9.
Further understanding of this variation is of importance because
CYP2C9, a principal-metabolizing enzyme of coumarins together
with VKORC1, is strongly involved in the development of drug side
effects seen in patients.
In addition to hepatocytes, GATA-mediated regulation of CYP2C9
also might be of physiological relevance in other tissues, in particular
in endothelial cells. CYP2C9 is expressed in these cells where it
metabolizes arachidonic acid into epoxyeicosatrienoic acids with a
concomitant generation of reactive oxygen species (Chehal and Gran-
ville, 2006). Both factors are important vasoreactive regulators and
are also involved in the pathogenesis of cardiovascular diseases.
GATA-2 is the most abundantly expressed GATA factor in endothe-
lial cells (Lee et al., 1991), and it is the key regulator of endothelial-
specific genes (Lugus et al., 2007). Further exploration of the
GATA-2 involvement in the regulation of CYP2C9 in the cardiovas-
cular system will certainly shed more light on the role of CYP2C9 in
vascular biology and cardiovascular diseases.
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